So­bi clos­es out 24-year part­ner­ship with Pfiz­er; Bel­gian Exothera site gets thumbs up from FDA

As So­bi’s drug sub­stance man­u­fac­tur­ing con­tract for Pfiz­er’s an­ti­he­mophilic drug ReFac­to ex­pires in Q1 of 2024, the com­pa­ny is mak­ing plans to cut staff at its Stock­holm, Swe­den, man­u­fac­tur­ing site.

The deal is end­ing more than a year ear­li­er than its orig­i­nal date at the end of 2025. The staff-cut­ting process will be­gin in the sec­ond half of this year, So­bi said in a press re­lease, elim­i­nat­ing 80 po­si­tions in the next two years. It’s the end of a part­ner­ship that be­gan in 1998.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER